When fear and misinformation go viral: Pharmacists' role in deterring medication misinformation during the 'infodemic' surrounding COVID-19

Abstract The world has faced an unprecedented challenge when coronavirus (COVID-19) emerged as a pandemic. Millions of people have contracted the virus and a significant number of them lost their lives, resulting in a tremendous social and economic shock across the globe. Amid the growing burden of the pandemic, there are parallel emergencies that need to be simultaneously tackled: the proliferation of fake medicines, fake news and medication misinformation surrounding COVID-19. Pharmacists are key health professionals with the required skills and training to contribute to the fight against these emergencies. Primarily, they can be a relevant source of accurate and reliable information to the public or other fellow health professionals thereby reducing the spread of COVID-19 medication misinformation. This can be achieved by providing accurate and reliable information based on recommendations given by relevant health authorities and professional associations to make sure the community understand the importance of the message and thus minimise the detrimental consequences of the pandemic. This commentary aims to summarise the existing literature in relation to the promising treatments currently under trial, the perils of falsified medications and medicine-related information and the role of pharmacists in taking a leading role in combating these parallel global emergencies.

[1]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[2]  D. Raoult,et al.  Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial , 2020, International Journal of Antimicrobial Agents.

[3]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[4]  gui-qiang Wang,et al.  A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease‐19 treatment option , 2020, Journal of medical virology.

[5]  Joshua D. Brown,et al.  Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine , 2020, Research in Social and Administrative Pharmacy.

[6]  Guangdi Li,et al.  Therapeutic options for the 2019 novel coronavirus (2019-nCoV) , 2020, Nature Reviews Drug Discovery.

[7]  J. Klingström,et al.  Nitric Oxide Inhibits the Replication Cycle of Severe Acute Respiratory Syndrome Coronavirus , 2005, Journal of Virology.

[8]  Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment , 2020, Case Medical Research.

[9]  Xiang Xie,et al.  COVID-19 and the cardiovascular system , 2020, Nature Reviews Cardiology.

[10]  Xu Liu,et al.  In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia , 2020, Case Medical Research.

[12]  Michael Roth,et al.  Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? , 2020, The Lancet Respiratory Medicine.

[13]  Jordan G Sheppard,et al.  Community pharmacists and communication in the time of COVID-19: Applying the health belief model , 2020, Research in Social and Administrative Pharmacy.

[14]  S. Ōmura,et al.  Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process , 2019, The Journal of Antibiotics.

[15]  Wu Zhong,et al.  Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study , 2020, Engineering.

[16]  P. Middleton,et al.  Ongoing Clinical Trials for the Management of the COVID-19 Pandemic , 2020, Trends in Pharmacological Sciences.

[17]  D. Jans,et al.  The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro , 2020, Antiviral Research.

[18]  N. Dong,et al.  Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China , 2020, bioRxiv.

[19]  E. Chorin,et al.  The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin , 2020, Nature Medicine.

[20]  P. Guérin,et al.  The consequence of COVID-19 on the global supply of medical products: Why Indian generics matter for the world? , 2020, F1000Research.

[21]  Xuhui Huang,et al.  Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro , 2020, Antiviral Research.

[22]  Joy Y. Feng,et al.  Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency , 2020, The Journal of Biological Chemistry.

[23]  E. Holmes,et al.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.

[24]  COVID‐19 in a designated infectious diseases hospital outside Hubei Province, China , 2020, Allergy.

[25]  Wu Zhong,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[26]  Centers for Disease Control and Prevention CDC COVID-19 Response Team Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[27]  Catherine S. K. Cheung,et al.  Anti‐inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: A randomized controlled trial , 2017, Antiviral research.

[28]  M. Martínez Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus , 2020, Antimicrobial Agents and Chemotherapy.

[29]  Sharon Einav,et al.  A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 , 2020, Journal of Critical Care.

[30]  C. Cheung,et al.  Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) , 2020, Journal of General Internal Medicine.

[31]  Philippe Brouqui,et al.  Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 , 2020, International Journal of Antimicrobial Agents.

[32]  J. Avorn,et al.  Drug Evaluation during the Covid-19 Pandemic. , 2020, The New England journal of medicine.

[33]  Erwan L'Her,et al.  Compassionate Use of Remdesivir for Patients with Severe Covid-19 , 2020, The New England journal of medicine.

[34]  A. Salazar-Ospina,et al.  How to link patients with suspicious COVID-19 to health system from the community pharmacies? A route proposal , 2020, Research in Social and Administrative Pharmacy.

[35]  Hongzhou Lu,et al.  [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. , 2020, Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences.

[36]  P. Ravaud,et al.  No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial , 2020, medRxiv.

[37]  Elsevier Sdol,et al.  Research in Social and Administrative Pharmacy , 2009 .

[38]  A. Khan,et al.  Assessment of efficacy of Oseltamivir-Azithromycin combination therapy in prevention of Influenza-A (H1N1)pdm09 infection complications and rapidity of symptoms relief , 2020, Expert review of respiratory medicine.

[39]  J. Wetterslev,et al.  Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. , 2016, The Cochrane database of systematic reviews.

[40]  Xiao-yan Liu,et al.  Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infection , 2020, medRxiv.

[41]  Bo Chen,et al.  Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial , 2020, medRxiv.

[42]  Jun Zhang,et al.  Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression , 2020, International Journal of Infectious Diseases.

[43]  J. Jackson,et al.  From the Editors’ Desk: The Importance of Screening for Depression in Primary Care , 2019, Journal of General Internal Medicine.

[44]  J. Low,et al.  Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. , 2020, JAMA.

[45]  D. Raoult,et al.  New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? , 2020, International Journal of Antimicrobial Agents.

[46]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[47]  O. Al-Quteimat,et al.  SARS-CoV-2 outbreak: How can pharmacists help? , 2020, Research in Social and Administrative Pharmacy.

[48]  M. Cascella,et al.  Features, Evaluation and Treatment Coronavirus (COVID-19) , 2020 .

[49]  Alexis Jacquier,et al.  Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study , 2020, Travel Medicine and Infectious Disease.

[50]  Z. Hong,et al.  Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study , 2020, Journal of Infection.

[51]  F. Hayden,et al.  Macrolides in critically ill patients with Middle East Respiratory Syndrome , 2019, International Journal of Infectious Diseases.

[52]  B. Bozkurt,et al.  Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19 , 2020, Journal of Cardiac Failure.

[53]  L. Nissen,et al.  Pharmacist role in vaccination: Evidence and challenges. , 2019, Vaccine.

[54]  S. P. Akpabio World Health Organisation , 1983, British Dental Journal.

[55]  D. Raoult,et al.  Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century , 2007, International Journal of Antimicrobial Agents.

[56]  Jing Yuan,et al.  Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury , 2020, Science China Life Sciences.

[57]  W. Liu,et al.  Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoV , 2020, Chembiochem : a European journal of chemical biology.

[58]  Alex A. Pollen,et al.  Zika virus cell tropism in the developing human brain and inhibition by azithromycin , 2016, Proceedings of the National Academy of Sciences.

[59]  G. Cheng,et al.  Azithromycin Protects against Zika Virus Infection by Upregulating Virus-Induced Type I and III Interferon Responses , 2019, Antimicrobial Agents and Chemotherapy.

[60]  Huan Li,et al.  Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Patients in Wuhan, China , 2020, medRxiv.

[61]  Yuan Wei,et al.  A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.

[62]  C. Whittaker,et al.  Estimates of the severity of coronavirus disease 2019: a model-based analysis , 2020, The Lancet Infectious Diseases.

[63]  C. Hughes,et al.  On the frontline against COVID-19: Community pharmacists’ contribution during a public health crisis , 2020, Research in Social and Administrative Pharmacy.

[64]  S. Kosari,et al.  Fake News: Medicines Misinformation by the Media , 2018, Clinical pharmacology and therapeutics.

[65]  Zhan Zhang,et al.  Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial , 2020, medRxiv.